Comparing the Outcome of Two Intraoperative Analgesia Techniques After Hepato-pancreato-biliary Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01201499 |
Recruitment Status : Unknown
Verified September 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Not yet recruiting
First Posted : September 14, 2010
Last Update Posted : September 14, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain Analgesia Sedation | Drug: Intrathecal morphine Drug: Continuous IV remifentanil | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 140 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | The Impact of Two Different Intraoperative Analgesia Techniques on Post-operative Outcome After Hepato-pancreato-biliary Surgery |
Study Start Date : | November 2010 |
Estimated Primary Completion Date : | November 2011 |
Estimated Study Completion Date : | January 2012 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Intrathecal morphine
A single shot of intrathecal morphine given before the induction of general anesthesia. Followed by postoperative IV patient-controlled morphine analgesia.
|
Drug: Intrathecal morphine
a single dose of intrathecal morphine (ITM, 4 µcg/kg, or ~0.1-0.3 mg morphine before induction of general anesthesia, followed by postoperative patient-controlled morphine analgesia (IV-PCA) for postoperative pain.
Other Name: ITM |
Active Comparator: Continuous IV remifentanil
Continuous administration of IV remifentanil during surgery, supported by a single bolus of IV morphine at the end of surgery. Followed by postoperative IV patient-controlled morphine analgesia.
|
Drug: Continuous IV remifentanil
a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
Other Name: IVR |
- postoperative pain [ Time Frame: 72 hours ]
Pain will be assessed 72 hours post-operatively by:
- A subjective visual analogue pain score (VAS, scale 0-10 cm) during rest, while coughing.
- Time to first postoperative request of analgesia (from IV PCA).
- Cumulative postoperative analgesia consumption (demand/delivery ratio).
- Need for supplementary of alternative analgesia
- Recovery and adverse effects [ Time Frame: 72 hours ]Secondary outcomes will include: levels of sedation, length of time with indwelling urinary catheter, time to ambulation (sitting, walking), length of stay in the intensive care unit (ICU) and total length of hospitalization, time to extubation, need for re-intubation and analgesia-related adverse effects.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
ASA physical status I-III patients (> 18 years old), scheduled for elective liver resection, pancreatic resection or pancreaticoduodenectomy ("Whipple" procedure) at Tel Aviv-Sourasky Medical Center.
Exclusion Criteria:
Contraindications to the spinal technique, allergy to the study drugs, patients treated with opioids for chronic pain, patients with obstructive sleep apnea, morbidly obese patients, pregnant women, patient requiring mechanical ventilation at the end of surgery.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01201499
Contact: Idit Matot, professor | 97236974758 | iditm@tasmc.health.gov.il | |
Contact: Miri Davidovich | 97236974758 | mirid@tasmc.health.gov.il |
Israel | |
Tel-Aviv Sourasky Medical Center | |
Tel-Aviv, Israel, 64239 | |
Contact: Idit Matot, professor 97236974758 iditm@tasmc.health.gov.il | |
Contact: Miri Davidovich 97236974758 mirid@tasmc.health.gov.il | |
Sub-Investigator: Yifat Klein, PhD | |
Sub-Investigator: Richard Nakache, MD | |
Sub-Investigator: Mendy Ben-Haim, MD | |
Sub-Investigator: Amir Szold, MD |
Study Chair: | Idit Matot, professor | Tel-Aviv Sourasky Medical Center | |
Principal Investigator: | Elena Parladansky, MD | Tel-Aviv Sourasky Medical Center |
Responsible Party: | Professor Idit Matot. Chair, Department of Anesthsiology & Intensive Care, Tel-Aviv Sourasky Medical Center |
ClinicalTrials.gov Identifier: | NCT01201499 |
Other Study ID Numbers: |
TASMC-10-IM-0073-CTIL |
First Posted: | September 14, 2010 Key Record Dates |
Last Update Posted: | September 14, 2010 |
Last Verified: | September 2010 |
Agnosia Perceptual Disorders Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Morphine Remifentanil |
Analgesics, Opioid Narcotics Central Nervous System Depressants Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents |